Beh Et S Disease Affecting Oral Mucosa — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for beh et s disease affecting oral mucosa. 23 active patents protecting 1 drugs from 1+ originators. First major cliff: 2028. Daily refresh.

1
Approved drugs
23
Active US patents
41/100
Avg vulnerability
$2.1B
Annual revenue covered

Originators in Beh Et S Disease Affecting Oral Mucosa

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Amgen 23 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating beh et s disease affecting oral mucosa. Each bar = one year. Y-axis scaled to peak year (13 patents).

7
28
13
34

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Otezla
APREMILAST
 Amgen 23 41 $2.1B 2028-02-16

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
7427638 Otezla other 58 2028-08-16
7427638 Otezla other 58 2028-08-16
7427638 Otezla other 58 2028-08-16
10092541 Otezla method of use 58 2034-05-29
11752129 Otezla method of use 58 2042-05-27
12427136 Otezla method of use 58 2042-05-27
10092541 Otezla method of use 45 2034-05-29
9872854 Otezla method of use 45 2034-05-29
9872854 Otezla method of use 45 2034-05-29
9872854 Otezla method of use 45 2034-05-29

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
7427638 Otezla composition of matter 5 2028-02-16
7427638 Otezla composition of matter 5 2028-02-16
7427638 Otezla composition of matter 5 2028-02-16
7427638 Otezla composition of matter 13 2028-02-16
11969409 Otezla formulation 38 2042-05-27
9872854 Otezla other 45 2034-11-29
10092541 Otezla other 45 2034-11-29
9872854 Otezla other 45 2034-11-29
9872854 Otezla other 45 2034-11-29
10092541 Otezla other 45 2034-11-29

Related